Results
| PMID | 23461865 |
| Gene Name | PAEP |
| Condition | Endometriosis (ovarian) |
| Association |
Associated |
| Population size | 99 |
| Population details | 99 (57 women with ovarian endometriosis, 42 healthy women control) |
| Sex | Female |
| Other associated phenotypes |
Ovarian endometriosis (OEM) |
|
Gynecol Endocrinol. 2013 May;29(5):455-9. doi: 10.3109/09513590.2013.769516. Epub Kocbek, Vida| Vouk, Katja| Mueller, Michael D| Rizner, Tea Lanisnik| Bersinger, Nick A Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg, 2, 1000 Ljubljana, Slovenia. The aim of this study was to evaluate serum and peritoneal fluid (PF) glycodelin-A concentrations in women with ovarian endometriosis. Ninety-nine matched pairs of serum and PF samples were included in our study. The case group comprised 57 women with ovarian endometriosis and the control group 42 healthy women undergoing sterilization or patients with benign ovarian cysts. Glycodelin-A concentrations were measured using ELISA. Endometriosis patients had significantly higher serum and PF glycodelin-A concentrations compared to controls, and this increase was observed in both proliferative and secretory cycle phases. Glycodelin-A concentrations were more than 10-fold higher in PF than in serum and correlated with each other. Intensity and frequency of menstrual pain positively correlated with glycodelin-A concentrations. Sensitivity and specificity of glycodelin-A as a biomarker for ovarian endometriosis were 82.1% and 78.4% in serum, and 79.7% and 77.5% in PF, respectively. These results indicate that Glycodelin-A has a potential role as a biomarker to be used in combination with other, independent marker molecules. Mesh Terms: Adult| Ascitic Fluid/*chemistry| Biomarkers/blood| Case-Control Studies| Endometriosis/*blood| Female| Glycodelin| Glycoproteins/*blood| Humans| Ovarian Diseases/*blood|DA 2014/01/15 06:00 |
|